Vistagen Therapeutics PH94B Phase 3 Trial Surpasses 80% Enrollment
During its Q3 2026 earnings call, Vistagen Therapeutics revealed its 220-patient PH94B Phase 3 trial has surpassed 80% enrollment and targets mid-2026 topline results. The company also flagged encouraging interim safety signals from its PST-VAL Phase 2 PTSD program, with full data due in Q4 2026.
1. Q3 Call Overview
Vistagen Therapeutics’ management conducted its Q3 2026 earnings call with no material revenue to report, emphasizing continued R&D investment and prioritizing detailed updates on its clinical pipeline developments over financial metrics.
2. PH94B Phase 3 Trial Progress
The Phase 3 study of PH94B for social anxiety disorder has enrolled over 80% of its 220-patient target, with the company affirming on-track recruitment and planning a mid-2026 topline efficacy and safety readout.
3. PST-VAL Phase 2 Update
Vistagen highlighted interim safety and preliminary efficacy signals from its PST-VAL Phase 2 trial in PTSD patients, confirming data collection is complete and full results are expected in Q4 2026 to inform a potential pivotal study design.